NCT02377427 - Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 25, 2015

Primary Completion Date

December 7, 2016

Study Completion Date

January 31, 2018

Conditions

Asthma

Interventions

DRUG

Mepolizumab

Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.

Trial Locations (16)

73112

GSK Investigational Site, Oklahoma City

92123

GSK Investigational Site, San Diego

97504

GSK Investigational Site, Medford

53792-9988

GSK Investigational Site, Madison

811-1394

GSK Investigational Site, Fukuoka

720-8520

GSK Investigational Site, Hiroshima

721-8511

GSK Investigational Site, Hiroshima

646-8558

GSK Investigational Site, Wakayama

90-329

GSK Investigational Site, Lodz

33-100

GSK Investigational Site, Tarnów

G514TF

GSK Investigational Site, Glasgow

L12 2AP

GSK Investigational Site, Liverpool

SE5 9RS

GSK Investigational Site, London

SW3 6NP

GSK Investigational Site, London

OX3 9DU

GSK Investigational Site, Oxford

S10 2TH

GSK Investigational Site, Sheffield